Leerink Partners Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

In a report released yesterday, Christopher Liu from Leerink Partners reiterated a Buy rating on Cogent Biosciences (COGTResearch Report). The company’s shares closed last Monday at $8.72.

According to, Liu is ranked 0 out of 5 stars with an average return of -20.9% and a 27.3% success rate. Liu covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Monte Rosa Therapeutics, and Nurix Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cogent Biosciences with a $27.00 average price target.

See the top stocks recommended by analysts >>

Based on Cogent Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $24.91 million. In comparison, last year the company had a GAAP net loss of $11.34 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Read More on COGT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More